Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD 923 (sublingual fentanyl) versus immediate-release morphine for breakthrough cancer pain
2005-002552-17Phase 3Terminated
- Sponsor
- Nxera Pharma
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of AD-923 in cancer pain and breakthrough cancer pain (BTcP) (2 arms), sponsored by Nxera Pharma. Primary endpoint: Sum of pain intensity difference (SPID) 0–30 minutes. Started Nov 2007; status: terminated.
02
Drugs
AD-923
03
Conditions
cancer painbreakthrough cancer pain (BTcP)
Beyond the preview
Go deeper on 2005-002552-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002552-17.